Inventors
Matthew Taylor
Assignees
Providence Health & Services – Oregon
Abstract
Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).